Ukrainian specialty law firm Mamunya IP has successfully represented Synthon B.V., an international pharmaceutical company specialized in science-centred developing and manufacturing high-quality generic and hybrid medicines, in a court dispute against Teva Pharmaceutical Industries Ltd and Yeda Research and Development Co. for invalidation of a patent related to the use of a medicinal product for the treatment of relapsing-remitting multiple sclerosis (RRMS), the most common type of multiple sclerosis.
By the resolution dated December 23, 2021, the Supreme Court upheld the previous courts’ decisions that unilaterally confirmed Synthon’s claims for invalidation of the patent concerning the drug for the treatment of RRMS, and brought to an end a four-year patent battle.
Oleksandr Mamunya, Managing Partner at Mamunya IP, commented: “The signal victory resulted from the well-designed litigation strategy and close cooperation with the client. This very complicated patent case involved, inter alia, three expert reports, cross-examination of four experts in pharmacology and patents, a chain of procedural challenges posed by the opponents, and required deep understanding of the Ukrainian patenting rules and practices”.
The firm’s core project team was led by the managing partner Oleksandr Mamunya, and included senior associate Oleksii Lukianov, associate Ilona Boliubash and patent attorney Anastasia Mindrul.